Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Higuchi

Showing results (201-210 of 286) with videos related to

Pageof 29
Sort By:
Cell Cycle (Georgetown, Tex.)|April 7, 2018
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancerKei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Frontiers in Oncology|December 24, 2025
Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expressionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|December 31, 2024
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse ModelsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|February 26, 2025
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting <i>Salmonella typhimurium</i> A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude MiceSei Morinaga, Ming Zhao, Kohei Mizuta, et al.
Cancer Diagnosis & Prognosis|January 6, 2025
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant DiseaseSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|December 3, 2024
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal FibroblastsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|October 30, 2024
Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Journal of Clinical Medicine|November 27, 2024
Serum Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibody Levels Are Involved in Rheumatoid Arthritis Complicated with Interstitial Lung DiseaseShomi Oka, Takashi Higuchi, Hiroshi Furukawa, et al.
Biochemical and Biophysical Research Communications|April 9, 2019
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse modelTakashi Higuchi, Kentaro Miyake, Hiromichi Oshiro, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancerMasuyo Miyake, Kentaro Miyake, Qinghong Han, et al.
Pageof 29

Showing results (201-210 of 286) with videos related to

Sort By:
Pageof 29
Cell Cycle (Georgetown, Tex.)|April 7, 2018
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancerKei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Frontiers in Oncology|December 24, 2025
Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expressionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|December 31, 2024
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse ModelsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|February 26, 2025
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting <i>Salmonella typhimurium</i> A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude MiceSei Morinaga, Ming Zhao, Kohei Mizuta, et al.
Cancer Diagnosis & Prognosis|January 6, 2025
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant DiseaseSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|December 3, 2024
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal FibroblastsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|October 30, 2024
Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Journal of Clinical Medicine|November 27, 2024
Serum Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibody Levels Are Involved in Rheumatoid Arthritis Complicated with Interstitial Lung DiseaseShomi Oka, Takashi Higuchi, Hiroshi Furukawa, et al.
Biochemical and Biophysical Research Communications|April 9, 2019
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse modelTakashi Higuchi, Kentaro Miyake, Hiromichi Oshiro, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancerMasuyo Miyake, Kentaro Miyake, Qinghong Han, et al.
Pageof 29